Pharvaris Prices $115 Million Equity Offering at $29.68 per Share
PHVS•Pharvaris has priced an underwritten offering of 3,874,664 ordinary shares at $29.68 each, raising approximately $115 million in gross proceeds before underwriting discounts and commissions. The offering includes a 30-day option for underwriters to purchase up to 581,199 additional shares and is expected to close around May 11, 2026.
1. Offering Details
Pharvaris launched an underwritten offering of 3,874,664 ordinary shares at $29.68 per share, generating gross proceeds of approximately $115 million before underwriting discounts and commissions.
2. Underwriters’ Option and Closing
The company granted underwriters a 30-day option to purchase up to 581,199 additional shares at the public offering price less discounts, with closing slated for on or about May 11, 2026, subject to customary closing conditions.
3. Capital Use and Pipeline
Net proceeds are expected to support the global pivotal Phase 3 CHAPTER-3 trial of deucrictibant extended-release tablets for hereditary angioedema prevention, regulatory submissions for immediate-release capsules, and the ongoing CREAATE Phase 3 study for acquired angioedema.
